ClinicalTrials.gg
Active, not recruitingNCT06269146Updated Oct 13, 2026

Pramipexole to Enhance Social Connections

A Phase 2 interventional study of Pramipexole Pill and Placebo Pill in Anxiety Disorders, Anxiety and Depression, sponsored by University of California, San Diego. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by University of California, San Diego · Phase 2, Interventional, and Treatment

How we know

Updated Oct 13, 2026Study documents postedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Anxiety Disorders by University of California, San Diego — 4 open to participants now, 5 under way, 1 of them phase 3. Anxiety Disorders · University of California, San Diego.

Planned enrollment
6th of 21
108 · median 60
Started
2024
with 2 others
Phase 2
Only one
of the 22
Registered
20th of 22
by date

Among the 22 studies in Anxiety Disorders by University of California, San Diego, this one is the 6th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2024, is the only one in phase 2, and was the 20th registered.

Anxiety Disorders

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

Browse Anxiety Disorders studies →

Open to participants now

4 of the 22 studies in Anxiety Disorders by University of California, San Diego are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 947 Anxiety Disorders studies recruiting now, 423 (45%) set no upper age limit and 455 (48%) stop at 75 or younger; 233 take children under 18; 319 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Anxiety Disorders by University of California, San Diego, or all of them as a file.
02

Study summary

This study seeks to understand if the medication pramipexole improves social connectedness and functioning in adults (ages 18-50) who experience anxiety or depression. The study plans to enroll 108 participants total across two sites (University of California San Diego and New York State Psychiatric Institute). Pramipexole will be given in a 6-week randomized, double-blind, placebo-controlled trial. Social reward processing will be assessed using measures of brain function (fMRI), behavior, and self-report at baseline and week 6. Knowledge gained from this study will help determine the therapeutic potential of targeting the dopamine system to remediate social disconnection as an anxiety and depression intervention.

Read the detailed description

This study seeks to understand how modulating functioning of the neurotransmitter dopamine affects brain circuits, behaviors, and subjective experiences that are believed to underlie an individual's motivation to establish and maintain positive social connections. This knowledge will help advance understanding of brain mechanisms that can be used to better treat social functioning impairments in people experiencing anxiety or depression. The R61 phase project will evaluate the effects of pramipexole (a medication that increases dopamine signaling in the brain) on responses to different types of positive social cues or contexts. The study drug will be given in a 6-week randomized, double-blind, placebo-controlled trial for individuals with clinical levels of anxiety or depression.

Aim 1 will test the hypothesis that pramipexole increases the anticipation of social rewards compared to placebo. Aim 2 will determine which dose of pramipexole (1.0 or 2.5 mg/d) produces a greater effect on social reward anticipation. To achieve these aims, approximately 108 participants (ages 18-50) with clinically elevated anxiety or depression will be randomized across two sites and randomized in equal proportions to one of two doses of pramipexole (1.0 mg/d or 2.5 mg/d) or placebo. They will complete standardized paradigms assessing social reward processing using measures of brain function (fMRI), behavior, and self-report at baseline and week 6. Knowledge gained from this study will help determine the therapeutic potential of targeting the dopamine system to remediate social disconnection.

03

Conditions studied

  • Anxiety Disorders
  • Anxiety
  • Depression
  • Social Disconnection

Keywords

  • Pramipexole
  • Anxiety
  • Depression
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinically elevated levels of anxiety (OASIS ≥ 8) or depression or (PHQ-9 ≥ 10).
  2. Moderate or greater social disability assessed with clinician-rating (SDS - Social ≥ 5).
  3. Below the normative mean for temperamental reward sensitivity (ATQ - Approach \< 35).
  4. Age 18-50.
  5. Ability to provide written .
  6. English proficiency.

Exclusion criteria

Exclusion Criteria:

Exclusion criteria are included to ensure that participation does not place subjects at undue risk, and to minimize confounding interpretation of our findings:

  1. Current, imminent risk of suicide assessed with Clinical Interview and Columbia Suicide Severity Rating Scale (C-SSRS) "yes" response to items 4, 5 (past month), 6 (past 3 months), or suicide attempt in the past year.
  2. History of bipolar or psychotic disorders.
  3. History of major neurological disorder or moderate to severe traumatic brain injury.
  4. History of severe or unstable medical conditions that might be compromised by participation in the study (e.g., cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease; history of seizure disorder).
  5. Past 6-month substance use disorder (any severity) with the exception of mild alcohol, cannabis, or tobacco use disorder, which will be permitted in the study.
  6. History of impulse control problems (e.g., pathological gambling).
  7. First-degree relative with a diagnosis of schizophrenia-spectrum or other psychotic disorder or bipolar disorder.
  8. History of cocaine or stimulant use (e.g., amphetamine, cocaine, methamphetamine; except for physician prescribed stimulants) in the past 6 months.
  9. History of dopaminergic agonists drug use (e.g., pramipexole, ropinirole, apomorphine, rotigotine) in the past 6 months.
  10. Positive urinalysis screen for psychoactive drug use (that is not physician prescribed or THC).
  11. Abnormal and blood count, liver, renal or findings as determined by physician.
  12. Women who are pregnant, breastfeeding, or planning to become pregnant within the next 6 months. Individuals of must agree to use an acceptable method of from at least 21 days prior to the first dose of study drug and for 3 months after the last dose of study drug for study entry.
  13. Concurrent empirically supported psychosocial treatments for anxiety or mood disorders (e.g., cognitive behavioral therapy).
  14. Use of any psychotropic medication (e.g. SSRIs, benzodiazepines) within 14 days before study entry [except for fluoxetine within 30 days]. Concurrent use is prohibited during the study
  15. Anticipated inability to attend regular study appointments.
  16. Anticipated inability to complete the study procedures as determined by study personnel.
  17. Clinical conditions assessed by the interviewer that necessitate more imminent clinical care. These criteria are in place so participants with these other, more severe symptoms can be referred for appropriate services (e.g. self-injurious behavior or exposure to a severe traumatic event in the past week).
  18. Non-correctable vision or hearing problems, as some tests require intact sensory functioning.
  19. No telephone or easy access to telephone.
  20. MRI
  21. CGI-S score of 6 or 7.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (estimated)

Study arms

  • Active comparator
    Pramipexole 1 mg/d

    Each participant will take pramipexole in identical capsular form twice daily for 6 weeks.

    Drug: Pramipexole Pill

  • Active comparator
    Pramipexole 2.5 mg/d

    Each participant will take pramipexole in identical capsular form twice daily for 6 weeks.

    Drug: Pramipexole Pill

  • Placebo comparator
    Placebo

    Each participant will take placebo in identical capsular form twice daily for 6 weeks.

    Drug: Placebo Pill

Interventions

  • DrugPramipexoleStudies of PramipexolePramipexole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The study drug, pramipexole, is an FDA-approved medication for the treatment of Parkinson's and restless leg syndrome. Pramipexole (Mirapex) tablets are taken orally, with or without food.

    Also known as: Mirapex

  • DrugPlacebo Pill

    Placebo will match the study drug in mode of administration, color, size, and taste.

06

What researchers measure

Primary outcomes

  1. Neural activation during social reward anticipation

    The primary outcome of interest is blood oxygen level dependent (BOLD) response during anticipation of positive valence social cues vs. baseline in the striatum region of interest (ROI) mask, defined according to a meta-analysis of the social incentive delay task.

    Time frame: Baseline, week 6

Secondary outcomes

  1. Neural activation during opportunities to disclose to others

    Blood oxygen level dependent (BOLD) response in the striatum region of interest (ROI) mask, defined according to a meta-analysis of the social incentive delay task, during share vs. private conditions of the disclosure task.

    Time frame: Baseline, week 6

  2. Motivation to engage in shared experiences with others

    Participants will make choices about whether to watch the same (Shared) vs. a different (Solo) videoclip from their partner. Each option is paired with a small monetary payoff that varies across options and trials. The point of subjective equivalence will be used to quantify the relative payoff difference at which people are indifferent to the two options (0 = maximizing monetary payoff; scores \< 0 represent greater value assigned to sharing experiences).

    Time frame: Baseline, week 6

  3. Positive affect in response to the social affiliation task

    The state version of the Positive and Negative Affect Schedule (PANAS) will be used to measure current ("right now") positive affect before (anticipatory) and after (responsiveness) the social affiliation task. Items are answered on a 5 point scale, 1 (Very slightly or not at all) to 5 (Extremely). The positive affect scale ranges from 10-50; higher scores indicate greater levels of positive affect.

    Time frame: Baseline, week 6

  4. Social approach goals during the social affiliation task

    Participants will rate 5 items describing approach-oriented goals focused on obtaining positive outcomes during the interaction. Items are answered on a 7-point scale with anchors of not at all and very much with higher scores indicating greater social approach goals.

    Time frame: Baseline, week 6

  5. Social approach behavior during the social affiliation task

    Observers will rate participant behavior on self-disclosure (the degree of personal information, thoughts, and feelings revealed) and responsiveness (verbal and nonverbal displays reflecting understanding, engagement, and validation). Items are answered on a 7 point scale, 1 (not at all) to 7(very much) with higher scores indicating greater levels of social approach behavior.

    Time frame: Baseline, week 6

  6. Future approach motivation

    The Desire for Future Interaction Scale (DFI) measures the degree to which respondents would be willing to affiliate with their conversation partner again. Items are answered on a 7 point scale, 1 (not at all) to 7 (very much) with higher scores indicating higher levels of future approach motivation.

    Time frame: Baseline, week 6

  7. Blood plasma pramipexole concentrations

    Time frame: Week 6

Other outcomes

  1. Negative affect in response to the social affiliation task

    The state version of the Positive and Negative Affect Schedule (PANAS) will be used to measure current ("right now") negative affect before (anticipatory) and after (responsiveness) the social affiliation task. Items are answered on a 5 point scale, 1 (Very slightly or not at all) to 5 (Extremely). The negative affect scale ranges from 10-50; higher scores indicate greater levels of negative affect.

    Time frame: Baseline, week 6

  2. Neural activation during social punishment anticipation

    Blood oxygen level dependent (BOLD) response during anticipation of negative valence social cues vs. baseline in the anterior insula and amygdala region of interest (ROI) mask, defined according to a meta-analysis of the social incentive delay task.

    Time frame: Baseline, week 6

  3. Social avoidance goals during the social affiliation task

    Participants will rate 5 items describing avoidance-oriented goals focused on avoiding negative outcomes during the interaction. Items are answered on a 7-point scale with anchors of not at all and very much with higher scores indicating greater social avoidance goals.

    Time frame: Baseline, week 6

  4. Anxious behavior during the social affiliation task

    Observer-rated participant behavior during the social affiliation task using items reflecting the anxiety-related behaviors commonly displayed during social-evaluative stress (e.g., fidget, appear tense or rigid). Items are rated on a 7-point scale from not at all to very much. Higher scores reflect greater anxious behavior.

    Time frame: Baseline, week 6

07

Study locations

2 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this study will be submitted to the National Institute of Health Data Archive (NDA).

Time frame: Every 6 months following the NDA submission schedule.

Access criteria: Eligible researches can submit a Data Access Request to the NDA to obtain access to de-identified study data for research purposes.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Nov 2026, 30 months after the start.

Of 81 non-industry phase 2 interventional studies under Anxiety Disorders, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's planned 30 months is below that.

Counting every sponsor, half of 96 studies reached it within 35 months; a quarter within 18 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2024
First posted
Feb 21, 2024
StartActual
May 13, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Mar 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Documents
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Documents Informed consent form ↗ posted
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06269146
Responsible party
Charles Taylor (Associate Professor, University of California, San Diego) — Principal investigator
First posted
Feb 21, 2024
Start date
May 13, 2024
Primary completion
Nov 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Charles Taylor, PhD
principal investigator · University of California, San Diego
Franklin Schneier, MD
principal investigator · New York State Psychiatric Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion